Monday, June 12, 2023

Program subject to change.

07:15 - 08:15 | BioIVT Industry-Sponsored Symposia | N002

Uncooperative Drugs in in vitro Transporter Research: Practical Approaches to Address Instability and Nonspecific Binding Challenges

Joanna Barbara, Ph.D., Site Lead, BioIVT

08:30 - 09:30 | Plenary Lecture 1 | Weston Auditorium

It Takes a Community: Creating Together in Science and Product Development
Suzanne Iverson, Toxicology Knowledge Team Sweden AB, Sweden

The DMDG Fellow lecture is an opportunity for the nominated individual to reflect on their achievements and contributions to science and the industry over their career. Presentations cover topics over many decades reflecting the advancement of knowledge over time in the field of DMPK and related sciences. Individuals also often acknowledge other key individuals/mentors/colleagues and friends who have influenced their career.

09:30 - 10:00 | Refreshment Break with Posters and Exhibitors | Cricket Hall Sports Village

10:00 - 12:00 | Parallel Symposia 1 and 2

Symposium 1: Harnessing –omics Approaches in Drug Development | N002
Chairs: Jim Monroe, MSD and Ian Copple, University of Liverpool, United Kingdom

An increasing number of repositories of omics data (genomics, proteomics, transcriptomics, metabolomics) are available, providing a rich source of data that can provide insight on cellular and organ level changes in disease and in pharmacological and toxicological response to drug treatment. This has huge potential in the drug discovery and development process from target identification to precision dosing and personalized medicine. This session discusses current applications of –omics data, challenges and the future potential of this exciting field.

Application of a Rat Liver Drug Bioactivation Transcriptional Response Assay that Informs on Potential for Drug-Induced Liver Injury
Jim Monroe, MSD

Generation of Blood-Brain Barrier Transporter Scaling Factors to Support in vitro-in vivo extrapolation (IVIVE)
Zubida Al-Majdoub, University of Manchester, Manchester, United Kingdom

Use of ‘Omics to Understand Species Differences in Sensitivity to Drug Induced Liver Injury
Ian Copple, University of Liverpool, Liverpool, United Kingdom

Symposium 2: Challenges and New Technologies in Delivering Brain Penetrant Therapies | Weston Auditorium
Chairs: Hugh Walton, Astex Theraputics and Scott Summerfield, Pharmaron

In the past decade we have seen several pharma companies pulling out from the CNS disease area, many indicating the lack of success in this area as a key issue. More recently, neurodegeneration has been identified as an area desperate for effective therapies and a growing patient need in an aging global population. This session will revisit successes of the past in delivering brain penetrant therapies and looking at current and future technologies that could improve efficacy by enhancing brain delivery for small molecules and biologics alike.

The Role of Kp,uu in CNS Drug Design - Current State and Horizon Beyond
Scott Summerfield, Pharmaron, Hoddesdon, United Kingdom

Can Carboxylic Acid Drugs be CNS Penetrant
Hugh Walton, Astex Therapeutics, Cambridge, United Kingdom

Challenges and Learnings in the Development of Brain Penetrating Large Molecule Therapeutics
Niels Janssen, F. Hoffman La Roche, Ltd.

12:00 - 12:30 | Admescope Showcase | N002

In vitro and in vivo Metabolism Studies with New Drug Modalities

Ari Tolonen, Ph.D., Admescope

12:00 - 13:30 | Exhibits Hall Hours and Lunch | Cricket Hall Sports Village

12:30 - 13:30 | Poster Presentations | Cricket Hall Sports Village

Poster Session 1: Posters A1 - A10

12:30 - 13:00: Pre-doc award finalist posters A1-A4
13:00 - 13:30: Post-doc award finalist posters A5-A10

This poster session is sponsored by SCIEX.

13:30 - 15:30 | Plenary Session 1 | Weston Auditorium

Plenary Session 1: Optimisation Challenges of Protein Degraders – Perspectives from DMPK and PK/PD Modeling
Chairs: Andreas Reichel, Bayer and Dermot McGinnity, AstraZeneca

This session will offer a drug metabolism and pharmacokinetics (DMPK) perspective on the optimisation of therapeutic protein degraders including oral protein degraders highlighting some of the challenges that they have presented to our established screening cascade. Furthermore, some of the perceptions and dogma surrounding the feasibility of oral protein degraders will be challenged by speakers demonstrating that acceptable oral PK properties for these modalities are achievable despite the physicochemical property challenges they present. The session will also illustrate how M&S can support various aspects throughout different phases of protein degraders development, from early research up to clinical development.

Optimising PROTACs for Oral Drug Delivery: A Drug Metabolism, PK and PKPD Perspective
Dermot McGinnity, AstraZeneca, Cambridge, United Kingdom

Physchem and Design Aspects Related to Drug Discovery of PROTACs: a Focus on ADME Properties
Giuseppe Ermondi, University of Turin, Turin, Italy

PK/PD-model Based Guidance of PROTAC Optimisation
Andreas Reichel, Bayer, Berlin, Germany

Translational PK/PD Modeling of PROTACs: a Case Study of STAT3 Degraders
Andreas Harsch, Kymera, Cambridge, Massachusetts, USA

15:30 - 16:00 | Refreshment Break with Exhibitors | Cricket Hall Sports Village

16:00 - 16:30 | 2023 ISSX Scientific Achievement Award Presentation and Lecture | Weston Auditorium

16:30 - 18:00 | Plenary Session 2 | Weston Auditorium

Plenary Session 2: Cutting Edge Science
Chairs: Nicola Wilsher, Astex Therapeutics and Roland Wolf, University of Dundee

PK Enhancing Co-therapies, Case Study of a Designed Co-therapy (Inqovi) Versus Repurposed Drugs
Aram Oganesian, Astex Pharmaceutials, Pleasanton, California, USA

Application of Mice Humanised for Pathways of Drug Disposition to Resolve Species Differences in Drug Discovery and Development
Roland Wolf, University of Dundee, Dundee, United Kingdom and Kenneth MacLeod, University of Dundee, Dundee, United Kingdom

Organ-on-chips for Improved Prediction of Human ADME Parameters
Yassen Abbas, CN-Bio Innovations, Cambridge, United Kingdom